Alzheimer’s and Gut Infection; Novel Tau Therapy; Kids’ Brain Structure and Drug Use

—
News and commentary from the world of neurology and neuroscience

by
Judy George, Deputy Managing Editor, MedPage Today

December 31, 2024

Alzheimer’s disease-associated CD83(+) microglia were linked with increased immunoglobulin G4 and human cytomegalovirus in the gut, vagal nerve, and brain. (Alzheimer’s & Dementia)

The Scientist explored the work of a researcher who had an unexpected finding while developing a novel anti-tau therapy.

Nicotinamide was safe but did not alter Alzheimer’s biomarkers in people with mild cognitive impairment or mild dementia, a phase IIa trial showed. (Neurology)

Neuroanatomical variability may confer a risk for early substance use in late childhood and adolescence, a large longitudinal study suggested. (JAMA Network Open)

A Manhattan appeals court said that a case alleging that Novartis paid doctors kickbacks to promote its multiple sclerosis drug fingolimod (Gilenya) can move forward. (Reuters via MSN)

The ACCORD-2 phase III trial of AXS-05 (dextromethorphan-bupropion) in Alzheimer’s disease agitation met its primary endpoint, Axsome Therapeutics said.

COVID-19 infection was not associated with changes in multiple sclerosis symptom severity or disability, longitudinal data showed. (Neurology)

Prodromal mood alterations were seen as early as 3 years before symptom onset in people with sporadic Creutzfeldt-Jakob disease in a case-control study. (JAMA Neurology)

A new brain map clarified neuronal connectivity behind motor function. (Neuron)